BRCA2 and prostate carcinoma: Integrative clinical genomics of advanced prostate cancer revealed that >10% of metastatic castration-resistant prostate cancers (mCRPCs) exhibit biallelic loss of BRCA2 42, and Olaparib has been approved to treat BRCA-mutant mCRPC6.